苏州天马精细化学品股份有限公司 2016 年第一季度报告正文 证券代码：002453 证券简称：天马精化 公告编号：2016-040 苏州天马精细化学品股份有限公司 2016 年第一季度报告正文 1 苏州天马精细化学品股份有限公司 2016 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人徐敏、主管会计工作负责人徐敏及会计机构负责人(会计主管人 员)李小芳声明：保证季度报告中财务报表的真实、准确、完整。 2 苏州天马精细化学品股份有限公司 2016 年第一季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 235,483,890.70 | 259,997,995.71 ...

Financial Performance - The company's operating revenue for 2015 was CNY 1,062,657,469.96, representing a 2.16% increase compared to CNY 1,040,177,839.83 in 2014[20]. - The net profit attributable to shareholders decreased by 30.02% to CNY 25,354,064.49 from CNY 36,228,495.76 in the previous year[20]. - The net profit after deducting non-recurring gains and losses fell by 51.69% to CNY 13,237,552.31 from CNY 27,400,793.55 in 2014[20]. - The net cash flow from operating activities surged by 453.88% to CNY 116,201,706.29, compared to CNY 20,979,494.71 in 2014[20]. - Basic earnings per share decreased by 33.33% to CNY 0.04 from CNY 0.06 in 2014[21]. - The total assets at the end of 2015 were CNY 1,947,752,084.50, a decrease of 0.91% from CNY 1,965,602,125.56 at the end of 2014[21]. - The net assets attributable to shareholders increased by 1.17% to CNY 1,199,947,174.17 from CNY 1,186,019,109.68 in 2014[21]. - The company reported a significant increase in cash flow from operations, indicating improved operational efficiency[20]. Investment and Acquisitions - The company is expanding its business scope through external investments, increasing the complexity of management and operational requirements[5]. - The company has diversified its business by acquiring stakes in health product companies, indicating a strategic shift towards the health sector[19]. - The company acquired 51% of Lifek for CNY 61.20 million, gaining control over the company[39]. - The company completed the acquisition of Fujian Lifek Pharmaceutical Co., Ltd., which was included in the consolidated financial statements[55]. - The company has allocated RMB 61.20 million from the raised funds for the acquisition of a 51% stake in Fujian Lifek Pharmaceutical Co., Ltd.[68]. - The company plans to use the remaining raised funds to acquire a 51% stake in Fick Pharmaceutical and permanently supplement working capital[75]. Research and Development - The company emphasizes R&D in paper chemicals, continuously developing new products and upgrading technology[39]. - Research and development efforts are focused on new chemical products, including amino acid derivatives and pharmaceutical intermediates, with a reported R&D expenditure of 10,194,318.7 CNY[80]. - The company is exploring opportunities in the biopharmaceutical sector, with plans to develop and market new health-related products[81]. Market and Operational Challenges - The company faces potential risks related to environmental protection due to its operations in the fine chemical and pharmaceutical industries[7]. - The company acknowledges the risk of not achieving expected returns on its fundraising investment projects due to market demand changes[6]. - The overall market environment remains challenging, with intense competition and low prices affecting profitability across various projects[71]. - The company faced challenges in the fine chemical industry due to a downturn in demand and oversupply, leading to lower-than-expected project returns[71]. Management and Governance - The company has established a performance-based salary system for management and a production-based salary system for grassroots employees to enhance motivation and performance[154]. - The company has implemented a systematic training management system to support continuous improvement in organizational capabilities[155]. - The governance structure of the company complies with the relevant regulatory requirements set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[158]. - The company has established strong relationships with major clients, including international firms like SK Group and Bayer, enhancing its market presence[35]. Shareholder and Equity Information - The company reported a profit distribution plan of 0.13 RMB per 10 shares, based on a total of 571,300,000 shares[8]. - The company’s profit distribution policy has been consistent with its articles of association and has been approved by the shareholders' meeting[88]. - The company declared a cash dividend of CNY 7,426,900 for the fiscal year 2015, which represents 100% of the distributable profit[92]. - The total distributable profit for the year was CNY 260,709,928.62, with cash dividends accounting for 100% of the profit distribution[92]. Employee and Workforce Information - The company employed a total of 1,620 staff, with 1,424 in production, 31 in sales, 104 in technical roles, 12 in finance, and 49 in administration[153]. - The company has a workforce of 168 employees with bachelor's degrees or higher, accounting for approximately 13% of total staff, which supports its R&D capabilities[33]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.1233 million[152]. Financial Controls and Audit - The audit opinion issued was a standard unqualified opinion, indicating that the financial statements fairly represent the company's financial position[173]. - There were no significant internal control deficiencies reported during the evaluation period, indicating robust internal governance[169]. - The company reported zero significant deficiencies in financial reporting controls[172].

苏州天马精细化学品股份有限公司 2015 年第三季度报告正文 证券代码：002453 证券简称：天马精化 公告编号：2015-069 苏州天马精细化学品股份有限公司 2015 年第三季度报告正文 1 苏州天马精细化学品股份有限公司 2015 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人徐敏、主管会计工作负责人李满义及会计机构负责人(会计主管人员)李小芳声明：保证季 度报告中财务报表的真实、准确、完整。 2 苏州天马精细化学品股份有限公司 2015 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,179,965,872.51 | 1,96 ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2015, representing a year-on-year increase of 15%[20] - The company's operating revenue for the current period is ¥566,290,894.70, representing a 14.28% increase compared to ¥495,507,815.32 in the same period last year[21] - The company aims to achieve a revenue target of RMB 1 billion for the full year 2015, indicating a growth forecast of 20%[20] - The company reported a total revenue of 12,928.08 million CNY for the first half of 2015, representing a 100.30% increase compared to the previous period[62] - The company's total revenue reached approximately $566.29 million, with a year-over-year increase of 17.06% in domestic revenue and 17.85% in international revenue[37] Profitability - Gross profit margin improved to 35%, up from 30% in the same period last year[20] - The net profit attributable to shareholders decreased by 8.31% to ¥27,373,946.22 from ¥29,853,487.96 year-on-year[21] - Net profit for the first half of 2015 was CNY 28,020,576.83, a decrease of 5.1% from CNY 29,538,052.44 in the previous year[135] - The net profit attributable to shareholders for the first nine months of 2015 is expected to range from 34.34 million to 46.46 million RMB, reflecting a change of -15.00% to 15.00% compared to the same period in 2014[71] Investment and R&D - The company plans to invest RMB 100 million in R&D for new product development in the next fiscal year[20] - Research and development expenses decreased by 36.28% to ¥9,333,790.92 from ¥14,648,544.08 due to slower project initiation[33] - The company is focusing on maximizing shareholder value and long-term sustainable development in light of current market conditions[61] - The company plans to fully launch new products from Tiankang Bio in September, following successful trial production[31] Market Expansion - User data indicates a 20% increase in customer base, reaching 10,000 active users[20] - The company has expanded its market presence in Southeast Asia, achieving a 25% growth in sales in that region[20] - The company is exploring potential acquisitions to enhance its market share and product offerings[20] - The company has acquired a 51% stake in Lifek, officially entering the health product manufacturing sector, with new products expected to launch soon[31] Financial Position - Total assets increased by 8.12% to ¥2,125,288,525.42 from ¥1,965,602,125.56 at the end of the previous year[21] - The company's total assets reached 30,689.4 million CNY, with a net profit of 1,245.45 million CNY for the reporting period[62] - The total amount of raised funds is CNY 479.33 million, with a net amount of CNY 465.96 million after deducting issuance costs[55] Cash Flow - The net cash flow from operating activities decreased by 13.90% to ¥105,939,177.46 from ¥123,044,180.97 in the previous year[21] - The cash flow from investing activities showed a net outflow of ¥139,062,339.31, a 288.78% increase in outflow compared to the previous year[34] - The total cash inflow from investment activities was 143,816,902.37 CNY, significantly higher than 81,522,754.55 CNY in the prior period, indicating a 76.4% increase[144] Corporate Governance - The governance structure of the company complies with regulatory requirements, ensuring strong independence and proper information disclosure[78] - The company has committed to strict compliance with laws and regulations to prevent the misuse of company funds[102] - There were no major litigation or arbitration matters during the reporting period[79] Shareholder Information - The total number of shares is 571.3 million, with 93.90% being unrestricted shares[109] - The company distributed a cash dividend of 0.2 RMB per share, totaling 11.43 million RMB, based on a total share capital of 57.13 million shares[73] - The controlling shareholder, Suzhou Tianma Pharmaceutical Group Co., Ltd., committed to not producing or developing any products that compete with those of the company and its subsidiaries[101] Challenges and Risks - The company faced challenges in achieving expected returns due to adverse macroeconomic conditions and industry overcapacity, leading to a decline in demand and prices[61] - The financial report indicates a commitment to maintaining consistent accounting policies across the company and its subsidiaries[177] - The company reported a decrease in total assets, with the year-end balance at 54,167,000.00[156] Compliance and Reporting - The semi-annual financial report has not been audited[104] - The company has not engaged in any significant research, communication, or interview activities during the reporting period[76] - The company has not encountered any litigation situations during the reporting period[53]

Financial Performance - The company's revenue for Q1 2015 was CNY 259,997,995.71, representing a 37.03% increase compared to CNY 189,740,825.68 in the same period last year[8] - Net profit attributable to shareholders decreased by 17.36% to CNY 10,652,232.47 from CNY 12,890,508.51 year-on-year[8] - Basic and diluted earnings per share dropped by 60.00% to CNY 0.02 from CNY 0.05 in the same period last year[8] - The net profit attributable to shareholders for the first half of 2015 is 24.2 million yuan, a decrease from 26.9 million yuan in the same period of 2014, representing a decline of approximately 6.5%[23] Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -22,011,675.87, a decline of 151.46% compared to CNY 42,771,790.15 in the previous year[8] - Net cash flow from operating activities decreased by 151.46% as a result of increased receivables from higher sales[15] - Total assets increased by 5.66% to CNY 2,076,871,787.92 from CNY 1,965,602,125.56 at the end of the previous year[8] - The company’s cash and cash equivalents increased by 41.76% due to new loans[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 35,889[11] - The largest shareholder, Suzhou Tianma Pharmaceutical Group Co., Ltd., held 25.98% of the shares, totaling 148,420,360 shares[11] - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[12] - A board member increased their shareholding by 1,390,000 shares, fulfilling a previous commitment[17] Government Support and Taxation - The company received government subsidies amounting to CNY 674,668.75 during the reporting period[9] - The company received a high-tech enterprise certificate, allowing it to enjoy a reduced corporate income tax rate of 15% for three years[16] Operational Performance - Operating revenue increased by 37.03% due to higher sales of the company's products[15] - Operating costs rose by 45.64%, attributed to increased sales of the company's products[15] - Financial expenses surged by 109.58% due to increased receivables leading to higher working capital requirements[15] - The company’s prepayments increased by 40.35% due to unfinished purchases at the end of the period[15] Future Outlook - The company expects a net profit attributable to shareholders to fluctuate between -10.00% and 10.00% for the first half of 2015[22] - The company anticipates a decline in gross margin due to intense competition in the traditional chemical market[23] - The newly acquired Runport Chemical is expected to incur significant upfront investment costs, contributing no profit in the short term[23] - The company's transformation is ongoing, with new business segments not yet contributing to profits in the first half of the year[23]

Financial Performance - The company's revenue for 2014 was approximately ¥1,040.18 million, a decrease of 7.27% compared to ¥1,121.67 million in 2013[27]. - The net profit attributable to shareholders for 2014 was ¥36.23 million, down 22.96% from ¥47.03 million in 2013[27]. - The net cash flow from operating activities decreased by 38.02% to ¥20.98 million in 2014 from ¥33.85 million in 2013[27]. - The total assets at the end of 2014 increased by 9.01% to approximately ¥1,965.60 million compared to ¥1,803.22 million at the end of 2013[27]. - The net assets attributable to shareholders rose by 1.78% to ¥1,186.02 million at the end of 2014 from ¥1,165.29 million at the end of 2013[27]. - The company achieved operating revenue of 1,040.18 million yuan in 2014, a decrease of 7.27% compared to 1,121.67 million yuan in 2013[36]. - The net profit attributable to shareholders was 36.23 million yuan, down 22.85% from the previous year[36]. - Total assets increased by 9.01% to 1,965.60 million yuan[36]. - The company reported a net profit of CNY 36,228,495.76 for the year 2014, with a total distributable profit of CNY 246,781,864.13 for shareholders[98]. Dividend Distribution - The company plans to distribute a cash dividend of 0.20 RMB per 10 shares based on a total of 571,300,000 shares, with no stock bonus[6]. - The company plans to distribute a cash dividend of 0.2 yuan per 10 shares, totaling 11,426,000 yuan for the year 2014, based on a total share capital of 57,130,000 shares[99]. - The cash dividend for 2014 represents 31.54% of the net profit attributable to shareholders, which is 36,228,495.76 yuan[100]. - The total distributable profit for shareholders at the end of 2014 is 246,781,864.13 yuan, after accounting for a 10% legal surplus reserve[102]. - The company has maintained a consistent cash dividend policy over the past three years, with cash dividends of 11,426,000 yuan in 2014, 14,282,500 yuan in 2013, and 36,000,000 yuan in 2012[100]. - The company’s cash dividends accounted for 100% of the total distributable profits in 2014[101]. Business Strategy and Growth - The company continues to pursue an external growth strategy through mergers and acquisitions, expanding its business scope and increasing the number of subsidiaries[15]. - The company is focusing on enhancing product quality management in response to the new GMP requirements[17]. - The company is expanding its business into the health products sector through a stake in Shen Yuan Bio[24]. - The company aims to solidify its traditional business segments, particularly in paper chemicals and pharmaceutical intermediates, while expanding its market share both domestically and internationally[85]. - The company aims to cultivate and expand the scale and variety of its active pharmaceutical ingredients (APIs) business, having acquired 100% equity of Tianli Pharmaceuticals in May 2013[86]. - The company is actively expanding its health products business, capitalizing on the growth potential of China's nutrition industry[87]. Environmental and Safety Compliance - The company has established a comprehensive environmental protection and governance system, ensuring compliance with national and local environmental standards[16]. - The production process involves handling hazardous materials, including a highly toxic gas, which poses safety risks despite existing safety measures[15]. - The company reported that its production processes generate waste that could impact the environment, highlighting the importance of ongoing environmental compliance efforts[16]. - The company did not experience any major safety incidents in 2014, adhering to its safety-first policy[35]. - The company adheres to environmental protection standards and has not experienced any major environmental pollution incidents[105]. Operational Challenges - The company faces operational risks due to the complexity of managing an expanding business and the need for effective integration of subsidiaries[15]. - The company acknowledges potential market risks affecting the expected returns from its fundraising investment projects, emphasizing cautious investment strategies[16]. - The company is facing challenges in talent acquisition and management, which may impact future growth and operational efficiency[88]. - The company’s rapid business expansion and the addition of subsidiaries will increase operational complexity and management demands[88]. Research and Development - Research and development expenses rose by 13.96% to 26.30 million yuan, reflecting increased investment in new product development[37]. - The company is committed to increasing R&D investment, enhancing hardware and talent acquisition, and accelerating the development of new products, particularly APIs[87]. Acquisitions and Investments - The company invested 32.20 million yuan for a 21.16% stake in Shenyuan Bio and established a joint venture, Tiankang Bio, with an investment of 10.20 million yuan for a 51% stake[33]. - The company acquired 85% of Zhenjiang Runport for 46.75 million yuan, becoming its controlling shareholder[33]. - The company completed the acquisition of 85% of Hong Kong Port Run Chemical Co., Ltd. for 46.75 million yuan, enhancing its competitive edge in the main business[112]. - The company has changed the use of raised funds amounting to 171.26 million RMB, which represents 36.75% of the total raised funds[70]. Governance and Management - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and management, ensuring accountability[5]. - The company has a diverse management team with experience in various sectors, including pharmaceuticals and chemical engineering[160]. - The company’s governance structure includes a remuneration committee that evaluates and determines compensation for directors and senior management[164]. - The company’s management emphasizes strict adherence to operational management systems to promote standardization and development[192]. Internal Control and Audit - The company has established a comprehensive internal control system in accordance with relevant laws and regulations, ensuring compliance and operational efficiency[192]. - No significant internal control deficiencies were found during the reporting period, indicating effective internal control measures[195]. - The audit opinion for the financial statements was a standard unqualified opinion, reflecting the reliability of the financial reporting[198].

苏州天马精细化学品股份有限公司 2014 年第三季度报告正文 证券代码：002453 证券简称：天马精化 公告编号：2014-057 苏州天马精细化学品股份有限公司 2014 年第三季度报告正文 1 苏州天马精细化学品股份有限公司 2014 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 苏州天马精细化学品股份有限公司 2014 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,879,906,808.02 | 1,803,216,536.65 | | 4.25% | | 归属于上市公司股东的净资产 | 1,190,188,650.29 | | 1, ...

Financial Performance - The company reported a revenue of RMB 200 million for the first half of 2014, representing a year-on-year increase of 15%[20] - The gross profit margin for the first half of 2014 was 30%, compared to 28% in the same period last year, indicating improved cost management[20] - The company reported a net profit of RMB 60 million for the first half of 2014, up 10% from the previous year[20] - The company's operating revenue for the current period is ¥495,507,815.32, a decrease of 1.05% compared to the same period last year[21] - Net profit attributable to shareholders is ¥29,853,487.96, an increase of 3.34% year-on-year[21] - The net profit after deducting non-recurring gains and losses is ¥26,884,544.87, a decrease of 2.66% compared to the previous year[21] - The net profit for the first half of 2014 was CNY 13,080,085.95, a decrease of 47.4% compared to CNY 24,866,330.83 in the same period of 2013[102] - Operating profit decreased to CNY 12,830,881.27, down 52.5% from CNY 27,057,801.10 year-on-year[102] - The net profit for the current period is 29,853,487.96, showing a decrease of 315,435.52 compared to the previous period[112] Investment and R&D - The company plans to invest RMB 50 million in R&D for new product development in the next fiscal year, focusing on specialty chemicals[20] - Research and development expenses rose significantly by 107.98% to ¥14,648,544.08 due to increased competition in the AKD raw powder market[29] - The company is exploring potential acquisitions in the specialty chemicals sector to enhance its product portfolio and market share[20] - The company has completed the acquisition of 100% equity in Shen Yuan Biological for a transaction price of 32,198,100 CNY, which is expected to enhance its competitiveness in the health product sector[64] Market Expansion - The company is expanding its market presence in Southeast Asia, with plans to establish a distribution center in Singapore by Q4 2014[20] - User data showed a 20% increase in customer base, reaching 1,500 active clients by the end of June 2014[20] - The company has established long-term partnerships with major international clients, including SK Group and Bayer, indicating strong market recognition[39] Financial Position - Total assets at the end of the reporting period reached ¥1,850,638,678.45, reflecting a growth of 2.63% from the end of the previous year[21] - The total amount of raised funds was ¥46,596.45 million, with ¥5,314.91 million invested during the reporting period[42] - The total assets of Suzhou Tianma Fine Chemical Co., Ltd. increased to CNY 1,850,638,678.45 from CNY 1,803,216,536.65, reflecting a growth of approximately 2.6%[91] - The company's total assets reached CNY 1,649,741,842.18, up from CNY 1,629,796,586.37[96] Cash Flow and Liquidity - The net cash flow from operating activities increased by 34.96% to ¥123,044,180.97[21] - Cash and cash equivalents increased slightly to CNY 182,214,961.18 from CNY 180,837,433.10, showing a growth of approximately 0.76%[91] - Cash and cash equivalents at the end of the period totaled CNY 162,982,060.99, down 69.6% from CNY 536,645,247.67 at the end of the previous period[106] - The company reported a cash outflow from investing activities of CNY 34,130,015.35, compared to an outflow of CNY 138,261,673.97 in the same period last year[106] Shareholder Information - The company has reported a total share count of 285,650,000 shares, with 77.87% being unrestricted shares[77] - The implementation of the 2013 profit distribution plan resulted in a dilution of earnings per share to CNY 0.05 for 2013 and CNY 0.06 for the first half of 2014[79] - The company has allocated 14,282,500.00 for profit distribution, which includes reserves and shareholder distributions[113] - The total number of common shareholders at the end of the reporting period is 15,885[80] Governance and Compliance - The company has established a robust governance structure, ensuring compliance with relevant laws and regulations, and enhancing information disclosure[60] - There were no significant litigation or arbitration matters during the reporting period[61] - The company addressed media concerns regarding the acquisition of Tianan Chemical's shares, confirming that the acquisition process was legally compliant and transparent[62] Operational Efficiency - The company is committed to sustainability and aims to reduce production waste by 15% by the end of 2014[20] - The company has developed a new production process for AKD, reducing reliance on imports and establishing a leading position in the domestic market[34] - The company has a strong talent pool with 181 employees holding at least a bachelor's degree, including 30 with master's or doctoral degrees, enhancing its R&D capabilities[37] Financial Reporting and Accounting - The financial statements are prepared in accordance with the Chinese accounting standards, ensuring compliance and transparency[130] - The consolidated financial statements include all subsidiaries, with adjustments made for long-term equity investments and intercompany transactions eliminated[138] - Cash and cash equivalents are defined as cash on hand and deposits that are readily available for payment, with cash equivalents being short-term, highly liquid investments[140]

2014 年第一季度报告正文 1 苏州天马精细化学品股份有限公司 2014 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人徐敏、主管会计工作负责人熊四华及会计机构负责人(会计主管 人员)李小芳声明：保证季度报告中财务报表的真实、准确、完整。 苏州天马精细化学品股份有限公司 2014 年第一季度报告正文 证券代码：002453 证券简称：天马精化 公告编号：2014-030 苏州天马精细化学品股份有限公司 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 189,740,825.68 | 226,852,340.71 | -16.36% | | 归属于上市公司股东的净利润（元） | 1 ...

Financial Performance - The company's operating revenue for 2013 was CNY 1,121,667,679.57, representing a 7.44% increase compared to CNY 1,044,015,398.04 in 2012[25]. - The net profit attributable to shareholders for 2013 was CNY 47,025,259.85, a decrease of 35.47% from CNY 72,873,412.42 in 2012[25]. - The net cash flow from operating activities was CNY 33,850,972.21, down 12.38% from CNY 38,634,747.13 in the previous year[25]. - The total assets at the end of 2013 amounted to CNY 1,803,216,536.65, an increase of 43.44% from CNY 1,257,150,845.53 at the end of 2012[25]. - The net assets attributable to shareholders increased by 59.79% to CNY 1,165,285,841.83 at the end of 2013, compared to CNY 729,276,533.30 at the end of 2012[25]. - The basic earnings per share for 2013 was CNY 0.18, a decrease of 40% from CNY 0.30 in 2012[25]. - The company achieved operating revenue of 1,121.67 million CNY in 2013, an increase of 7.44% compared to the previous year[34]. - The net profit attributable to shareholders was 47.03 million CNY, a decrease of 35.47% year-on-year[34]. - Total assets increased by 43.44% to 1,803.22 million CNY[34]. Investment and Financing - The company has raised funds through a non-public offering to finance four investment projects, which are expected to positively impact the company's strategic development and operational scale[14]. - The company raised 466 million CNY through a non-public stock issuance of 45.65 million shares for project construction[30]. - The total amount of raised funds is 46,596.45 million RMB, with 21,789.93 million RMB utilized during the reporting period[66]. - The company has invested 8,645.77 million RMB directly into fundraising projects and replaced 13,144.16 million RMB of self-owned funds[66]. - The total cash inflow from financing activities increased by 110.23% to ¥997,088,791.69, primarily due to non-public stock issuance[48]. Risk Management - The company faces operational management risks due to rapid expansion and increased complexity from new subsidiaries, which may affect efficiency and performance if not managed properly[14]. - Safety production risks are present due to the handling of flammable and explosive chemicals, and the production of toxic gases, despite having safety measures in place[14]. - The company acknowledges potential market risks related to the demand and pricing fluctuations of its expanded product capacities post-investment[14]. - The company faces potential risks related to environmental protection and may need to increase investments in compliance with stricter future regulations[16]. - The management of accounts receivable is critical as the company expands into domestic and international markets, with a focus on maintaining control over receivables[16]. - The company is at risk of losing tax benefits if it fails to meet the standards for high-tech enterprises or if national policies change[16]. Product Development and R&D - The company is involved in the production of fine chemicals, which is a strategic focus in the global chemical industry[10]. - The company has developed various products, including AKD and amino acid protecting agents, which are essential in the paper and pharmaceutical industries[11]. - R&D expenditure increased by 17.21% to 23.08 million CNY, supporting new product development[35]. - The company has developed a new production process for AKD, reducing reliance on imports and enhancing domestic production capabilities[57]. - The company plans to continue developing new products and technologies in the chemical manufacturing sector[75]. Market Expansion - The company is actively expanding its market presence and product offerings, which may include new technologies and products in the future[14]. - The company has established strong partnerships with major clients in the paper and pharmaceutical industries, including international firms like Bayer and SK Group[61]. - Domestic sales accounted for CNY 716.2 million, representing a 12.12% increase compared to the previous year, while international sales reached CNY 343.1 million, up by 6.58%[51]. Corporate Governance and Compliance - The company has established a quality management system to enhance customer satisfaction and protect the rights of suppliers and customers, adhering to fair procurement practices[95]. - The company has implemented a comprehensive human resources management system, detailing regulations on recruitment, training, and performance evaluation[94]. - The company has established a harmonious labor relationship by listening to employee feedback through a representative assembly[94]. - The company has maintained strict adherence to commitments made regarding competition and fund usage[114]. - The company has established a comprehensive internal control system to ensure compliance with laws and regulations, enhancing the quality of financial reporting and operational management[180]. Shareholder Returns - The company plans to distribute a cash dividend of 0.50 RMB per 10 shares to all shareholders based on the total share capital as of December 31, 2013[5]. - The proposed cash dividend for 2013 is 0.5 CNY per 10 shares (including tax), totaling 14,282,500 CNY, with no bonus shares issued[90]. - The cash dividend payout ratio for 2013 is 30.37% of the net profit attributable to shareholders[91]. - The company’s profit distribution policy is in compliance with the latest regulations from the China Securities Regulatory Commission[90]. - The company has maintained a positive retained earnings balance, allowing for consistent dividend distributions[93]. Subsidiary Performance - Tianhe Chemical, a subsidiary, reported total assets of CNY 207.79 million and net profit of CNY 15.99 million[72]. - Shandong Tianan Chemical, another subsidiary, had total assets of CNY 586.26 million and a net loss of CNY 0.38 million[72]. - Nantong Nabaiyuan Chemical, a subsidiary, reported total assets of CNY 259.29 million and net profit of CNY 4.31 million[72]. - Suzhou Zhongke, a subsidiary, had total assets of CNY 14.42 million and a net loss of CNY 1.59 million[74]. Employee Management - The company employs approximately 185 staff with higher education, contributing to its R&D and technical service capabilities, which supports its competitive edge in product development[59]. - The educational background of employees shows that 77% have less than a college degree, while only 2% hold a master's degree or higher[157]. - The company has no retired employees requiring financial support as of December 31, 2013[159]. Strategic Acquisitions - The company acquired 100% equity of Suzhou Tianli Raw Materials in May 2013, marking a significant step towards integrating raw material production[77]. - The acquisition of Tianli Raw Material Pharmaceutical allows the company to strengthen its strategic position in the pharmaceutical industry[104]. - The company is in the process of acquiring the remaining 39.5% equity of Zhongke Tianma, which will lead to its absorption and merger[107]. Safety and Environmental Responsibility - The company has maintained a good safety record in production, adhering to GMP quality systems and environmental health and safety standards[96]. - The company has not experienced any major environmental pollution incidents and complies with national and local environmental protection standards[96]. - The company emphasizes employee rights protection, conducting regular health check-ups and providing necessary safety training and protective equipment[94].